12 AI News and Ratings Investors are Keeping Their Eye On

Page 2 of 11

10. Acrivon Therapeutics, Inc. (NASDAQ:ACRV)

Number of Hedge Fund Holders: 9

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) is a clinical-stage biopharmaceutical company developing precision oncology drugs using its AI-powered AP3 platform to match treatments with patients based on tumor-specific sensitivities.

On February 5, Acrivon Therapeutics announced that the FDA has granted Breakthrough Device designation for its ACR-368 OncoSignature assay, which identifies endometrial cancer patients who may benefit from ACR-368 treatment. The proprietary biomarker assay is developed using Acrivon’s AI-driven AP3 platform and is being used in a Phase 2b trial to predict patient response. Recent clinical data from ESMO 2024 showed a significant correlation between biomarker-positive patients and treatment response. Acrivon also continues enrollment for ACR-368 and its Phase 1 WEE1/PKMYT1 (protein kinases that regulate the cell cycle) inhibitor, ACR-2316.

Page 2 of 11